Skip to content
Biodatica
Start free

Novita Pharmaceuticals, Inc.

Scottsdale, Arizona

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

3mo agoTrial registeredApr 14, 2026Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

349 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2/PHASE3 registered

    Dec 29, 2025

    Platinum-resistant Ovarian Cancer · ACTIVE_NOT_RECRUITING · sponsor: Novita Pharmaceuticals, Inc. · Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

    ClinicalTrials.gov · NCT07109414 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Dec 7, 2021

    Advanced or Metastatic Solid Tumor Malignancies · ACTIVE_NOT_RECRUITING · sponsor: Novita Pharmaceuticals, Inc. · NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

    ClinicalTrials.gov · NCT05023486 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 21, 2017

    Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies · COMPLETED · sponsor: Novita Pharmaceuticals, Inc. · Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

    ClinicalTrials.gov · NCT03199586 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources